These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36031856)

  • 1. Approximate Bayesian computation design for phase I clinical trials.
    Jin H; Du W; Yin G
    Stat Methods Med Res; 2022 Dec; 31(12):2310-2322. PubMed ID: 36031856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the relative efficiency of model-assisted designs: a conditional approach.
    Lin R; Yuan Y
    J Biopharm Stat; 2019; 29(4):648-662. PubMed ID: 31258039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial design for drug combinations with Bayesian model averaging.
    Jin IH; Huo L; Yin G; Yuan Y
    Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
    Liu R; Lin J; Li P
    Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials.
    Lin R; Yin G; Shi H
    Biostatistics; 2023 Apr; 24(2):277-294. PubMed ID: 34296266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
    Cunanan K; Koopmeiners JS
    BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CFO: Calibration-free odds design for phase I/II clinical trials.
    Jin H; Yin G
    Stat Methods Med Res; 2022 Jun; 31(6):1051-1066. PubMed ID: 35238697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An optimization algorithm for designing phase I cancer clinical trials.
    Jiang H; Liu Y; Su Z
    Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of design methods for a safety run-in phase of a phase II clinical trial.
    Ji L; Alonzo TA
    Clin Trials; 2023 Apr; 20(2):181-191. PubMed ID: 36628921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonparametric overdose control with late-onset toxicity in phase I clinical trials.
    Lin R; Yin G
    Biostatistics; 2017 Jan; 18(1):180-194. PubMed ID: 27549121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
    Tang N; Wang S; Ye G
    BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.